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Application of Constrained Optimization Methods:  
Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force 
 
Abstract 
Constrained optimization methods are already widely used in healthcare to solve problems that 
represent traditional applications of operations research methods such as choosing the optimal 
location for new facilities or making the most efficient use of operating room capacity.  In this 
paper we illustrate the potential utility of these methods for finding optimal solutions to problems 
in healthcare delivery and policy.  To do so, we selected three award-winning papers in 
healthcare delivery or policy development reflecting a range of optimization algorithms.  
 
Two of the three papers are reviewed using the ISPOR Constrained Optimization Good Practice 
Checklist adapted from the framework presented in the initial Optimization Task Force Report. 
The first case study illustrates application of linear programming to determine the optimal mix of 
screening and vaccination strategies for the prevention of cervical cancer.  The second case 
illustrates application of the Markov Decision Process to find the optimal strategy for treating 
Type-2 diabetes patients for hypercholesterolemia using statins. 
 
The third paper is used as an education tool. The goal is to describe the characteristics of a 
radiation therapy optimization problem and then invite the reader to formulate the mathematical 
model for solving it.  This example is particularly interesting because it lends itself to a range of 
possible models, including linear, non-linear, and mixed-integer programming formulations.  
From the case studies presented, we hope the reader will develop an appreciation for the wide 
range of problem types that can be addressed with constrained optimization methods, as well as 
the variety of methods available. 
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Highlights 
- Constrained optimization methods are informative to decision makers in providing 
insights about optimal target solutions and the magnitude of the loss of benefit or 
increased costs associated with the ultimate clinical decision or policy choice.  Failing to 
identify a mathematically superior or optimal solution represents a missed opportunity to 
improve economic efficiency in the delivery of care and clinical outcomes for patients. 
  
- 7KH,63252SWLPL]DWLRQ0HWKRGV(PHUJLQJ*RRG3UDFWLFHV7DVN)RUFH¶VILUVWUHSRUW
provided an introduction to constrained optimization methods to solve important clinical 
and health policy problems.  This report also outlined the relationship of constrained 
optimization methods relative to traditional health economic modeling, graphically 
illustrated a simple formulation and identified some of the major variants of constrained 
optimization models, such as linear programming, dynamic programming, integer 
programming, and stochastic programming. 
  
- This second report illustrates the application of constrained optimization methods in 
healthcare decision making using three case studies.  The studies focus on determining 
optimal screening and vaccination strategies for cervical cancer, optimal statin start times 
for diabetes and an educational case to invite the reader to formulate radiation therapy 
optimization problems.  These illustrate a wide range of problem types that can be 
addressed with constrained optimization methods. 
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Background to the Task Force - Box 
The proposal to initiate an ISPOR Good Practices for Outcomes Research task force was 
evaluated by the ISPOR Health Science Policy Council then recommended to the ISPOR Board 
of Directors for approval. 
 
The task force was comprised of international subject matter experts representing a diverse range 
of stakeholder perspectives (academia, research organizations, government, regulatory agencies 
and commercial entities).  The task force met approximately every five weeks by teleconference 
and in person at ISPOR conferences. All task force members reviewed many drafts of the report 
and provided frequent feedback in both oral and written comments. 
 
To ensure that ISPOR Good Practices Task Force Reports are consensus reports, findings and 
recommendations are presented and discussed at ISPOR conferences.  In addition, the first and 
ILQDOGUDIWUHSRUWVDUHFLUFXODWHGWRWKHWDVNIRUFH¶VUHYLHZJURXS$OOUHYLHZHUFRPPHQWVDUH
considered.   Comments are addressed as appropriate in subsequent versions of the report.  Most 
are substantive and constructive improving the report. 
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1. Introduction 
 
There are often many different options for improving healthcare policy or improving current 
practice in healthcare organizations.  The optimal solution among those options, i.e., the 
solution that best achieves a defined goal, such as maximizing patient quality-of-life or 
minimizing patient waiting time for services, may not be readily apparent.  Constrained 
optimization methods use mathematical techniques to help efficiently and systematically 
identify the best (optimal) of all possible solutions to a problem while considering the relevant 
constraints, such as budget limits or staffing capacity.  
 
Of course, mathematically optimal solutions to all problems are not always feasible; other non-
quantifiable criteria such as political barriers that cannot be accounted for by defined constraints 
have to be considered.  However, optimization techniques can still be highly informative to 
decision makers in providing insights about optimal target solutions and the magnitude of the 
loss of benefit or increased costs associated with the ultimate policy choice.  In healthcare, 
failing to identify a mathematically superior or optimal solution represents a missed opportunity 
to improve economic efficiency in the delivery of care and clinical outcomes for patients.   
 
The ISPOR Optimization Methods Emerging Good Practices Task Force provided an 
introduction to constrained optimization methods to solve important health policy and clinical 
problems in its first report [1].  The previous report outlined the relationship of constrained 
optimization methods relative to traditional health economic modeling and simulation models 
and identified some of the major variants of constrained optimization models, such as linear 
programming, dynamic programming, integer programming, and stochastic programming.  
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In addition, the report graphically illustrated the formulation and solution of a straightforward 
integer program to maximize health benefit subject to a budget constraint.  Further, it explained 
the steps in an optimization process:  1) structuring the problem, 2) formulating the mathematical 
model, 3) developing the model, 4) validating the model, 5) selecting the optimization method, 
6) performing the optimization and conducting sensitivity analysis, 7) reporting results, and 8) 
using the results for decision-making.   
 
The principal objective of this second Optimization Task Force Report is to illustrate the 
application of constrained optimization methods in healthcare decision making.  To identify 
relevant examples, we began by searching for award-winning health care papers from the 
Institute for Operations Research and Management Sciences (INFORMS) and the Association 
for European Operations Research Societies (EURO). From these papers, we then selected 
examples with models relevant for health economic policy or clinical decision making. Finally, 
we endeavored to select papers that collectively illustrated a variety of different constrained 
optimization methods. The three papers that received the most votes from the task force 
members were selected.   
In this report, two of these three papers are compared with the steps in formulating, solving, 
validating, reporting, and using optimization models originally published as Table 3 in the first 
Optimization Emerging Good Practices Task Force Report. A slightly modified version of this 
previous table is presented as the ISPOR Constrained Optimization Good Practice Checklist 
(Table 1) in the current report.  The first case study illustrates the application of linear 
programming to determine the optimal mix of screening and vaccination strategies for the 
prevention of cervical cancer [2].   
  
8 
 
The second case illustrates application of the Markov Decision Process to find the optimal 
strategy for treating Type-2 diabetes patients for hypercholesterolemia using statins [3]. Finally, 
the third paper is used as an education tool. The goal is to describe the characteristics of a 
radiation therapy optimization problem and then invite the reader to formulate the mathematical 
model for solving it.  This example is interesting because it lends itself to a range of possible 
models, including linear, non-linear, and mixed-integer programming formulations.  (Detailed 
formulations for each model are provided in Appendix 1.)   
Although we are clearly limited in the number of permutations that we can present with these 
three cases we hope the reader will develop a sense of the wide range of problem types that can 
be addressed with constrained optimization methods, as well as the variety of methods available.   
 
2. Overview of applications of constrained optimization in health care 
Constrained optimization methods are already widely used in healthcare areas such as choosing 
the optimal location for new facilities, making the most efficient use of operating room capacity, 
workforce planning, etc.  They can also be instrumental in guiding clinical decision making in 
actual clinical practice where health professionals and patients face constraints, such as 
proximity to treatment centers, health insurance benefit designs, and the limited availability of 
health resources.  
 
Optimization is also beneficial for planning healthcare expenditure.  An obvious example is the 
resource allocation problem faced by a planner with a number of investment opportunities, but a 
fixed budget inadequate to fund all available opportunities [4].  Perhaps the simplest case of this 
is where the investment opportunities are incremental to current care, and fall into distinct 
FDWHJRULHVHJFKLOGUHQ¶VVHUYLFHVFDUGLRYDVFXODUGLVHDVHFDQFHUUHVSLUDWRU\GLVHDVHDQG
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mental health) with separate budgets [5].  In this situation, decisions about investments in 
different clinical areas can be made independently of one another.  
 
However, more commonly the healthcare budget needs to be allocated across different 
conditions. The problem of choosing the best set of investment opportunities to fund under a 
fixed budget constraint in order to meet an objective, such as maximizing total QALYs can be 
addressed as an optimization problem [6]. Given a number of eligible interventions and a fixed 
budget, optimization can be used to solve resource allocation problems.  
 
In fact, the task central to health economic analysis, of evaluating whether the incremental cost-
effectiveness ratio (ICER) of an intervention is below a critical threshold, can be shown to be 
related to budget constrained optimization. According to the theoretical definition, under a strict 
set of assumptions, the threshold represents the inverse of the shadow price of the budget 
constraint ± the shadow price is defined as how much the objective (QALYs) would increase for 
a one-unit increase in the constraint (budget) [7].    
 
Other resource allocation problems may be even more complicated.  There may be significant 
and complex interactions between different investments; and there may be additional constraints 
to be considered such as limits on the number of staff or bed capacity [8].   For example, 
consider the case of allocating resources for the prevention and cure of an infectious disease such 
as HIV, Hepatitis C, tuberculosis, malaria, or polio [9, 10].  If the planner invests in vaccination, 
there may be fewer cases to treat in the future (and so investment in highly capital-intensive 
treatment facilities may be wasted).  On the other hand, vaccination is itself costly, and if the 
disease has a low prevalence, it may be more cost-effective to target the treatment [11].  For 
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more details on these complexities, see the Economic Analysis of Vaccination Programs: An 
ISPOR Good Practices Task Force Report [12].   
 
Optimizing investment in such infectious disease programs is more complicated because they 
may involve making multiple runs of a state-of-the-art simulation [13, 14] of the infectious 
disease dynamics, to plot out how the particular patterns of resource allocation perform against 
the objective (of minimizing the total number of cases or maximizing the probability of 
achieving disease eradication). For a review of mathematical approaches to infectious disease 
prediction and control, see [15]. 
 
In other settings, the critical resource(s) might not be money; for example, when allocating 
donated organs such as kidneys not every kidney will be compatible with every donor.  In 
addition, the medical condition of the eligible recipients will be different, some will be more 
urgent than others.  In this case, the underlying problem can be categorized as a matching 
problem [16].  In matching problems, not everyone will get the best match.  However, the 
objective with kidney allocation is generally to ensure that as few as possible people and kidneys 
are left unmatched (patients without kidneys; kidneys without patients) [17] present a discussion 
about how to incorporate fairness in such problems.  Some measures of deservingness, e.g., time 
on waiting list, may be incorporated in the objective function.  Nevertheless, some fairness 
considerations may also be included as constraints, e.g., at least x % of transplants should go to 
patients of a certain blood type. The 2012 Nobel Prize in Economics was awarded to Shapley 
and Roth, in part for their work in stable matchings applied to organ donation.   
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Other clinical problems where optimization can be applied relate to problems of disease 
management, e.g., timing of the initiation of treatment, or the sequence of treatments.  The 
promise of health gain from treatment must be balanced against reasons for holding off 
treatment, which may include cost, undesirable side-effects, and emergent drug resistance.  It 
may be the case that there is an optimal stage in the disease prognosis or poinWLQWKHSDWLHQW¶V
life cycle where the balance shifts from favoring non-intervention to favoring treatment.  The 
MDP approach provides an ideal framework [18] to study such problems for identifying critical 
initiation points.  This framework has been used to analyze timing decisions in diseases as 
diverse as HIV, diabetes, and breast cancer [3, 19, 20]. Optimization methods can be applied to 
identify the optimal treatment sequences when a large number of treatments are available--for 
example, in rheumatoid arthritis [21]. 
 
Finally, constrained optimization methods have also been applied to disease diagnosis [22, 23], 
the development of optimal treatment algorithms [24, 25], and the optimal design of clinical 
trials [26]. Health technology assessment using tools from constrained optimization methods is 
also gaining popularity [27]. We also encourage the readers to refer to the initial ISPOR 
Optimization Emerging Good Practices Task Force Report, which presented a more 
comprehensive overview of the different applications for which optimization techniques can be 
used [1]. 
 
3. Steps in an Optimization Process 
Table 1 reproduces the steps of the optimization process previously presented in the initial 
Optimization Task Force Report. It is reproduced here as the ISPOR Constrained Optimization 
Good Practice Checklist to reduce reader burden as the two case studies and the educational 
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example will all be discussed in light of this framework. The primary purpose of Table 1 is to 
support the design of optimization studies by prompting the user to report and justify the choices 
made at each step of the process. It should be noted that the steps outlined in Table 1 do not need 
to be conducted sequentially. In fact, most of the optimization studies involve performing these 
steps in an iterative manner to solve the problem. Along with guiding the design of optimization 
studies, Table 1 can also be used to support the critique and quality assessment of published 
optimization studies. The steps in Table 1 are described in detail in the text below. 
 
Problem structuring 
The first step is to determine if constrained optimization is an appropriate methodology to 
address the problem at hand. It involves identifying if there are any quantifiable constraints and 
whether a specific goal can be achieved by changing some (decision) variables. This problem 
structuring phase should be done in consultation with the key stakeholders and decision makers 
to ensure that the optimization problem is appropriately specified. This will ensure that the 
REMHFWLYHIXQFWLRQVDQGFRQVWUDLQWVDUHDSSURSULDWHDQGJHWWKHLUµEX\-LQ¶WRFKDQJHWKHGHFLVLRQ
variables in order to achieve an optimal solution. A clear textual description of the decision 
problem should be reported and validated with the key stakeholders and decision makers. 
 
Mathematical formulation 
This involves converting the textual description into a mathematical representation of the 
optimization problem. Objective function(s) and constraints need to be defined in analytical form 
as a function of decision variables and parameters. Note that decision variables are changed 
during optimization iterations in order to identify the optimal solution, while parameters remain 
fixed. The number and type of decision variables (continuous or discrete) as well as the 
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parameters need to be justified. The type of objective function (single objective or multi-
objective, linear or non-linear, stochastic or deterministic) and the type of estimation (analytical 
estimation or via simulation modelling for complex problems) need to be specified. Similarly, 
for constraints, the number of constraints and the type of estimation used for the constrained 
quantity need to be reported and justified. The sources and the values of the parameters used to 
estimate the objective function(s) and constraints also need to be justified. The mathematical 
representation of the optimization problem should be reported after validation with the key 
stakeholders and decision makers. 
 
Model development 
This involves programming the model in software to estimate the objective function(s) and 
constraints, using decision variables and parameters as inputs. It should be noted that in some 
instances, the analytical form of the mathematical formulation can be programmed directly 
because the mathematical formulation sufficiently defines the relationships between objective 
function(s)/constraints and decision variables/parameters. However, in other instances, a 
simulation model needs to be developed to estimate the objective function(s)/constraints. Models 
should be designed so that the objective function can be evaluated based upon the full range of 
possible decision variables (the feasible region or search space). The model structure and 
assumptions should be reported and validated with the key stakeholders and decision makers.  
The initial mathematical formulation and model development steps affect the specification of the 
particular optimization method to be applied. These steps are closely related and interdependent.  
This is one important reason why the steps in optimization do not always have to follow the 
order described in Table 1. 
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Model validation 
Before the optimization is undertaken, the underlying model needs to be verified and validated, 
to ensure the robustness of the results for different analyses performed.  This means that the 
model should be consistent with reality within specified tolerances. Once the model has been 
developed to the point where it is producing estimates, the model code also needs to be checked 
to ensure the model results are valid. In the case of models that represent an analytical 
formulation directly, this is relatively straightforward as this involves checking the specific 
model results used as parameters for estimating the objective function and constraints.  
 
However, when a simulation model is used to evaluate the objective function, this would 
necessitate a combined approach of simulation-optimization [28, 29].  This is a bit more difficult 
because it involves checking the model results for all combinations of decision variables.  Meta-
modeling techniques [30], i.e., modeling the simulation model outputs as functions of simulation 
inputs, can circumvent getting the simulation results for all variables in the parameter space. 
These topics are beyond the scope of this report; we suggest reviewing Sargent (2009) and Law 
(2006).   
 
Modelers are encouraged to validate the model results in different parts of the decision variable 
space to have enough confidence that the model used is appropriate for optimization [31, 32]. 
This should also involve asking the key stakeholders and decision makers to check the model 
results for face validity. 
 
Select optimization method 
The choice of optimization method needs to be justified on the basis of the type of decision 
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variables (continuous or discrete), and the type of objective function (single objective or multi-
objective, linear or non-linear, stochastic or deterministic), and the type of constraints (single vs 
multiple constraints). The optimization algorithm/tool used also needs to be justified on the basis 
of the optimization method, as well as the estimation type (analytical formulation vs simulation 
optimization) and other relevant characteristics of the model (number of decision variables or 
transferability of the problem to other well-known problem types). The methods and tools chosen 
for optimization need to be reported and justified. 
 
Perform optimization/sensitivity analysis 
This involves running the optimization model, identifying the optimal solution, and 
understanding the impact of alternative parameters on the optimal solution using sensitivity 
analyses.  Settings used for the optimization, such as the convergence level required or the 
maximum number of iterations, need to be justified. In some problems, searching for the optimal 
solution might be computationally feasible, whereas in others, solving time increases to such an 
extent that the use of heuristics is justified. 
 
As with decision modelling, optimization can have stochastic uncertainty in parameters and 
model structure. Stochastic optimization [33], robust optimization techniques [34] and sensitivity 
analyses can be used to deal with parameter uncertainty.  However, structural uncertainty needs 
to be dealt with by thinking about the choices throughout the optimization process. For example, 
is a linear program really appropriate?  Are the simplifications and assumptions appropriate and 
to what extent is there a risk of a wrong/sub-optimal decision being reached? The choice of 
decision variables, parameters, constraints, and model assumptions also need to be structurally 
evaluated.    
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The optimal solution needs to be checked to identify if it is feasible and, if so, sensitivity 
analyses should be conducted. The optimization settings and the sensitivity analyses need to be 
explained to the key stakeholders/decision makers and reported in detail.  
 
Report results 
This involves specifying the values of the decision variables, objective function and constraints 
at the optimal solution, for the base case analyses, as well as the sensitivity analyses. The 
optimization results (i.e. optimal solution for the base case and sensitivity analyses) need to be 
reported and validated with the key stakeholders/decision makers. Also, the performance of the 
optimization tool/method needs to be reported, such as the time taken to identify the optimal 
solution, number of iterations required, and the convergence level (if applicable). These results 
should be reported in a manner that is understandable and interpretable by relevant stakeholders 
and decision makers. 
 
Decision making 
The meaning of the optimal solution should be explained to the decision makers.  This involves 
converting the mathematical optimal solution into clear, concise plans for implementation.  At 
this stage, the choices made at all the stages of modelling and optimization--type of model, data, 
assumptions, the design, settings and others--need to be validated to ensure the results of 
optimization problem are plausible and consistent with decision maker objectives.  Also, the 
possibility of amending the decision variables to the values specified by the optimization process 
need to be checked with the stakeholders to ensure that the implementation is feasible.  
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To reiterate, the results of the optimization should not be used mechanistically: it is the decision 
makers that implement the findings, hence they should be comfortable with the methodology, 
data, and assumptions involved in the whole optimization process. 
 
4. Optimization Case Studies 
In this section, we consider two constrained optimization studies and compare their structure to 
the steps outlined in Table 1.  The first case study focuses on resource allocation for the 
prevention/cure of infectious diseases while the second illustrates the use of constrained 
optimization to guide optimal treatment initiation. These cases illustrate different modeling 
techniques, as well as extensions of the application of constrained optimization methods beyond 
the typical realm of scheduling, shipping cost minimization, maximization of facility capacity, 
etc.    Please note that the educational case study and the model formulations appear in Appendix 
I and II, respectively.  
 
Case Study 1. Selecting a Mix of Prevention Strategies Against Cervical Cancer [2] 
Problem Structuring  
Cervical cancer is the second most common cancer in women under 35 years old in the UK. The 
objective of this study was to identify the optimal mix of primary and secondary prevention 
strategies for cervical cancer that achieves maximum reduction in cancer cases under budget and 
logistic constraints.  The authors applied the optimization model in two countries with different 
healthcare organizations, epidemiology, screening practices, resource settings and treatment 
costs: one in the UK, and one in Brazil. They considered two cervical cancer prevention 
strategies against human papillomavirus (HPV): 
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x Primary prevention ± Because an HPV infection is the most common cause of cervical 
cancer, HPV vaccination is a primary prevention strategy. Two HPV vaccines are 
currently available.  Both vaccines have an efficacy of approximately 98% against the 
cervical cancer vaccine HPV types (HPV 16 and 18), but with a different cross-protection 
profile against oncogenic non-vaccine HPV-types. The implementation of vaccination 
varies widely among countries with regard to the strategy selection (national 
immunization program or individual based); the logistics (via a separately established 
vaccination setting or via primary healthcare); the age group targeted; and the gender 
selection (female only or all patients). 
 
x Secondary prevention - Cytology-based screening programs have contributed to a 
decrease of up to 80% in the incidence and mortality of cervical cancer in countries with 
a well-established, organized screening program. However, despite their potential, 
cytology-based screening programs sometimes have a limited impact due to factors such 
as sensitivity of the screening method (ability of the test to correctly identify those 
patients with the disease), treatment failure and the level of resources required for an 
adequate follow-up of patients. 
 
Four prevention strategies were evaluated: screening; vaccination; screening plus vaccination; 
and no prevention because these were the options available for cervical cancer prevention in the 
UK and Brazil at the time of the study. Only cytology-based screening was included in the 
model, with sensitivity estimates based on published literature. Different screening interval 
scenarios were explored, from every year to every 25 year.  Women are screened only twice over 
their lifetime with a 1-year increment between each scenario.   
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It was assumed that vaccination is administered at age 12 and induces lifelong protection against 
HPV. In total, 52 different strategies were tested for each country. These 52 strategies defined 
the full range of possible combinations of vaccination (not available or available) and screening 
interventions (not available or available with intervals between screenings estimated from 1 year 
to 25 years in 1-year increments).  The final scenarios can be listed as follows: (scenario 1: no 
screening & no vaccine; scenario 2: 1-year screening interval & no vaccine; scenario 3: 2-year 
screening & no vaccine; « , scenario 26\HDUVFUHHQLQJ	QRYDFFLQH¶scenario 27: no 
screening & vaccine; scenario 28: 1 year screening & vaccine; scenario 29: 2 year screening & 
YDFFLQH«scenario 52: 25-year screening & vaccine). 
 
Mathematical Formulation  
The optimization model used a linear programming formulation consisting of a single linear 
objective function and multiple linear constraints.  The model was continuous, allowing 
fractional values for the decision variables.  It was static, meaning that the problem was solved 
once at steady state.  Finally, the model was deterministic which assumed that all the outputs 
were known and there was no stochastic variation.  
Fifty-two decision variables, D?H?, each representing the proportion of the population addressed by 
each strategy considered, D? ൌ  ?ǡ  ?ǡ ǥ ǡ ? ?, were used with separate identifiers for strategies 
involving screening and strategies involving vaccination in order to deal with screening and 
vaccination coverage constraints. Given the aim was to minimize the number of cervical cancer 
cases, the objective function was represented as the sum of the cervical cancer cases (at steady 
state for 100 000 women) for each strategy, D?D?H?, multiplied by the proportion of population 
receiving each strategy, D?H?.  
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The linear programming formulation for the cervical cancer prevention strategy optimization is 
given as 
PLQ ෍ D?D?H??H?H?H?H?H?H?  (1) 
VXEMHFWWR ෍ D?H?D?H?൑ D?H?H?H?H?H?  
(budget constraint) 
(2) 
  ? ൑ D?H?൑  ?ǡ D?D?D?D? ൌ  ?ǡ ?ǡ ǥ ǡ ? ? 
(strategy coverage bounds) 
(3) 
 ෍ D?H?ൌ  ?H?H?H?H?H?  
(complete population distribution) 
(4) 
 ෍ D?H?H?H?H?H?H?൅  ෍ D?H?H?H?H?H?H? ൑ D?D?D?H? 
(screening coverage upper bound) 
(5) 
  ෍ D?H?H?H?H?H?H? ൑ D?D?D?H? 
(vaccination coverage upper bound) 
(6) 
 D?H?൑ ሺ ? െ D?D?D?H?ǡ  ? െ D?D?D?H?ሻ 
(upper bound on population with no coverage) 
(7) 
 
 D?H?א D?ǡ D?D?D?D? ൌ  ?ǡ ?ǡ ǥ ǡ ?  
 
(8) 
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The model has five constraints: budget, strategy coverage, total population, screening and 
vaccination coverage limits. The first constraint is to ensure that the sum of the cost for each 
strategy (at steady state for 100000 women), D?H?,  multiplied by the proportion of the population 
receiving each strategy, D?H?, is less than the overall budget constraint, D?.  The strategy coverage 
constraint ensures that the proportion of each strategy is between 0 and 1.  The complete 
population distribution constraint guarantees that all the 52 variables add to 1.  That is, the sum 
of the proportion of the population receiving each strategy should reflect the entire population.  
Also, the sum of the proportion of the population receiving strategies including screening should 
be less than the government-imposed screening coverage limit, D?D?D?H?. Similarly, the sum of 
proportion of population receiving strategies including vaccination should be less than the 
externally (e.g., government) imposed vaccination coverage limit, D?D?D?H?. Note that the 
parameters D?D?H? and D?H? are derived from the Markov cohort model (see details below) for each 
strategy D?.  
Model Development 
The mathematical formulation described above used the outputs of a health economic Markov 
cohort model (number of cervical cancer cases CCi and total costs bi for each strategy i) as input 
parameters. The Markov cohort model describes the population level¶V natural history of cervical 
cancer for the evaluation of the clinical and economic consequences of different prevention 
strategies. The model considers a population of 100,000 women under a given prevention 
strategy at steady state level. The Markov model consists of following states: no HPV infection, 
HPV infection, cervical intraepithelial neoplasia (CIN) stages, cancer, and death (both cancer 
and non-cancer related).  
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Once patients are infected with HPV, individuals can progress and regress from HPV infection 
and CIN stages. Vaccination is assumed to reduce the HPV infection rates, and detection through 
screening provides the possibility of the treatment of CIN. Overall vaccine efficacy in the UK 
and Brazil was calculated from the country-specific proportions of each HPV type in cervical 
cancer. Other clinical and cost inputs were specified of each of these two countries. 
The time horizon of the optimization problem was one year, and the health/cost outcomes across 
the whole population were derived from the lifetime cohort results from the Markov model.  
The model was run with a cohort of women over their lifetime for each one of the 52 scenarios 
described above separately for both countries. The results of each scenario were used to estimate 
the number of cervical cancer cases and total costs expected over one year at steady state for 100 
000 women. The estimated number of cervical cancer cases (D?D?H?) and total costs (D?H?) of each of 
the 52 prevention strategies were then used as input parameters for the optimization model. 
Model validation 
No validation effort was reported, neither for the health economic model nor for the optimization 
model. 
Select optimization method 
Due to the relatively small size of the linear programming formulation described above--a total 
of 52 decision variables and 57 constraints--a standard primal simplex method was chosen to 
solve the problem.   
Perform optimization/sensitivity analysis 
This optimization problem was programmed in Microsoft Excel as a linear program and solved 
using the Solver Add-on. This tool uses the simplex method to identify the optimal mix of the 52 
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cervical cancer prevention strategies that minimize the expected cervical cancer cases under a 
fixed budget, as well as screening and vaccination coverage constraints. The optimization model 
was solved twice using separate parameter sets reflecting the settings in UK and Brazil.  
The base-case analysis assumed that the maximum screening coverage is the pre-vaccination 
coverage rate (65% in the UK and 50% in Brazil), maximum vaccination coverage was set to 
80%, and the overall budget was the pre-vaccination budget allotted to screening and treatment 
of cervical lesions. No explanation was given as to why these maximum coverage rates were 
chosen in the base-case.  
Sensitivity analyses were performed to understand the effect of altering the budget or the 
achievable screening or vaccination coverages (the constraints in the model) as well as the 
duration of vaccine protection which was one of the parameters in the economic modeling.  The 
budget constraint was varied from a 20% reduction to a 150% increase over the pre-vaccination 
levels, while the screening and the vaccination coverage levels were varied from 0% to 100%. 
 
Report results  
The optimal mix of strategies in the UK was 65% vaccination plus screening with a screening 
interval of 6 years, and 15% vaccination alone. In Brazil, the optimal mix was 50% vaccination 
plus screening with a screening interval of 5 years, and 30% vaccination alone. These optimal 
mixes of strategies would result in a reduction of cervical cancer by 41% in the UK and 54% in 
Brazil from pre-vaccination levels with no budget increase. It can be easily observed that in both 
countries, the optimal coverage rates for both preventive interventions are at the maximum levels 
permitted in the model. 
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In the sensitivity analyses, increasing the budget permits a shortening of the screening interval, 
but the effect on the reduction in cervical cancer cases is modest and tends to reach an early 
plateau. Vaccination alone (screening coverage set to 0%) could provide a reduction in cervical 
cancer cases compared with the pre-vaccination situation of screening alone with a lower budget.  
In both countries, the effect of reduced vaccine efficacy duration (25 years compared with 
lifetime) still results in a reduction in cervical cancer compared with the pre-vaccination strategy, 
but not as much as the base-case analysis. In both countries, a sharp reduction in the expected 
number of cervical cancers is seen when the vaccine coverage rate exceeds the maximum 
screening coverage rate or when screening coverage rate exceeds the maximum vaccine coverage 
rate while maintaining the budget (treatment and prevention) constraint. 
 
Decision Making  
In this case study, within the same budget, results of the optimization program show that it would 
be possible to substantially reduce the number of cervical cancer cases by implementing an 
optimal combination of HPV vaccination (80% coverage) and screening at pre-vaccination 
coverage (65% UK, 50% Brazil) while extending the screening interval to every 6 years in the 
UK and 5 years in Brazil. 
 
Optimization models can be used to determine the optimal mix of primary and secondary 
prevention strategies minimizing cervical cancer burden under budget and logistic/infrastructure 
constraints. The key strength of optimization modeling is its ability to evaluate multiple 
combinations of different interventions and identify the mix that provides the maximum expected 
health benefit (reduction in cervical cancer cases) at the expected costs within the available 
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budget. In addition, it allows the decision maker to set constraints reflecting local conditions, 
such as a limited available budget or limited achievable coverage rates.  
 
In this paper, the optimization model uses the health economic model outcomes as its input 
parameters. Therefore, the validity of the optimization results is based on the validity of the 
health economic model. Furthermore, the implementation issues, such as how it will be decided 
who will receive vaccination, screening or both, were not discussed. In its current form, the 
optimization model is used more to demonstrate the potential value of adding vaccination 
strategy and to coordinate this addition with the existing screening practices in the UK and 
Brazilian health systems.  
 
For implementation purposes, a more advanced optimization model, as well as a more detailed 
health economic model that takes into additional considerations and interactions, (e.g. herd 
protection, resistance dynamics of the virus, transmission to the others, decreased secondary 
infections, infertility avoidance, logistic/infrastructure, socio-economic and equity concerns, 
etc.), are needed. Lack of these essential considerations in the economic and optimization models 
limits the usefulness of the results provided in the paper. 
 
Case Study 2: Optimizing statin treatment initiation using MDP [3] 
Problem Structuring  
Type-2 diabetes (T2D) leads to many chronic outcomes, including stroke, coronary heart disease 
(CHD), kidney failure, etc.  This study focuses on the selection of T2D patients for statin therapy 
of hypercholesterolemia. The market for statins is significant and remains burdensome to health 
system costs despite the availability of generics. Furthermore, there are a number of studies that 
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report overprescribing (prescribing statins to those patients who only achieve marginal benefit) 
and under-prescribing (not prescribing statins to those patients most likely to benefit). Given this 
GHEDWH'HQWRQDQGFROOHDJXHV¶DLPZDVWRLGHQWLI\WKHRSWLPDOWLPHWRLQLWLDWHVWDWLQWUHDWPHQW
for hypercholesterolemia in T2D patients. 
 
The problem is set up using an MDP framework.  Traditional health services research methods 
focus on efficacy and/or cost-effectiveness at a snapshot in time to inform decisions, while MDP 
provides an in-depth modeling and understanding for optimal decisions at multiple time points 
RYHUDSDWLHQW¶VGLVHDVHKLVWRU\'XHWRWKHQDWXUHRIWKHPRGHOing, it provides the ability to 
personalize decisions, as opposed to one-size-fits-all policies and guidelines established for 
medical decisions.  However, similar to other approaches, MDPs have assumptions based on data 
and/or the structure of the model. 
 
Mathematical Formulation   
The model optimizes a cost-reward function over time using a MDP.  We recognize that MDPs 
are not commonly associated with constrained optimization because they typically do not have 
³FRQVWUDLQWV´LQWKHVDPHVHQVHWKDWWKHWHUP is used in the mathematical programming literature 
(for example, in the previous case study).  However, the ability of dynamic programming models 
to identify the optimal solution to the MDP--the optimal pattern of statin therapy initiation over 
time--provides an excellent example of a clinical use case for constrained optimization as long as 
one recognizes that constraints in a MDP are implicitly defined based upon allowable transitions 
between states and/or available decisions within each state.  
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The structure of the model reflects shared decision-making by providers and patients over time 
as a function of patient age, patient clinical history, and several health states. History is 
dependent on CHD or stroke, as well as nine cholesterol levels pertaining to low, medium or 
high HDL and LDL levels. Patient information aligning with the data across three major heart 
studies provides much higher sensitivity to the proper time to initiate and maintain a statin 
regimen. The MDP model determines the optimal decision at each epoch, to maximize the 
overall rewards D?ሺD?H?ሻwhile accounting for costs of all future states.  
 
Reward function: D?D?D?D?ሺD?H?ሻ ൌ D?ೞ՜ሾ ? ൫D?H?ವH?൯D?ሺD?H?ǡ D?ሺD?H?ሻሻሿH?H?H?H? ׊D?H?א D?Ԧ where t is a time index for 
discrete decision epochs, D?H?is an index for states at time period D? ൌ  ?ǡ ǥ ǡ ǡ  D?ሺD?H?ሻis the statin 
treatment decision at time D? ൌ  ?ǡ ǥ , D?D?ሾ ?ǡ ?ሿ discounts the objective function depicting reduced 
value of rewards in future years, and D?H? is the number of years in a decision epoch. 
 
Reward function for each time period: D?൫D?H?ǡ D?ሺD?H?ሻ൯ ൌ D?H?ൣD?ሺD?H?ሻ െ ൫D?D?H?ሺD?H?ሻ ൅ D?D?H?H?H?ሺD?H?ሻ൯ െD?ሺD?H?ሻD?H?H?൧ െ ൣD?H?൫D?H?ǡ D?ሺD?H?ሻ൯ ൅ D?H?H?H?൫D?H?ǡ D?ሺD?H?ሻ൯൧ where ND reflects the number of years in a 
decision epoch, D?ሺD?H?ሻǡ D?ሺD?ሻD?ǡ D?D?H?ሺD?H?ሻD?ǡ D?D?H?H?H?ሺD?H?ሻ D?ǡCS(sT) is the one time cost of stroke occurring in period t. 
 
Reward function for final time period: D?൫D?H?ǡ D?ሺD?H?ሻ൯ ൌ D?H?ൣD?ሺD?H?ሻ െ ൫D?D?H?ሺD?H?ሻ ൅ D?D?H?H?H?ሺD?H?ሻ൯ െD?ሺD?H?ሻD?H?H?൧ െ ൣD?H?൫D?H?ǡ D?ሺD?H?ሻ൯ ൅ D?H?H?H?൫D?H?ǡ D?ሺD?H?ሻ൯൧ ൅ D?ሾD?D?D⨇?ȁ ?H?ǡ D?ሺD?H?ሻሿ, where D?ሾD?D?D⨇?ȁ ?H?ǡ D?ሺD?H?ሻሿis the post-decision horizon expected reward. The authors separate the time 
horizon into a decision horizon and a post-decision horizon. While the decisions are only made 
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during the decision horizon, the rewards from the post-decision horizon still need to be included. 
For instance, while the decision to initiate statin therapy is only until age 80, the rewards of 
treatment after age 80, need to be included in the model. 
 
Model Development 
The starting age of the patients in the model was 40, and it was assumed that the patients could 
start statin treatment at any point between 40 and 80 in 2-year increments. If all these treatment 
options were modeled as separate scenarios, as is common in both clinical trials and economic 
evaluations, the problem would soon become quite complicated, especially if these treatment 
options were compared incrementally.  
 
+RZHYHUXVLQJRSWLPL]DWLRQWHFKQLTXHVRQHFDQLGHQWLI\D³VLQJOH´RSWLPDODJHIRULQLWLDWLQJ
VWDWLQWUHDWPHQWWKDWPD[LPL]HVWKHµUHZDUG¶IXQFWLRQ7KHDuthors interpreted reward in terms of 
expected net monetary benefit E(NMB) as a function of quality-adjusted life years (QALYs), 
Cost and willingness-to-pay threshold (Ȝ), that is: 
 
(10% ǻ4$/<VȜ± ǻ&RVW   (9) 
 
Model Validation 
The authors do not describe the model validation process, although it is clear from the 
PDQXVFULSW¶VDcknowledgements section that the authors interacted extensively with experts 
within the clinical system where the research was conducted, as well as with external reviewers. 
 
Select Optimization Method   
The problem is set up using a MDP.  The MDP framework is intended for dynamic streams of 
decisions (i.e. decisions made over time).  The time horizon and the time steps are identified as 
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indices for decision epochs.  Each decision in the stream guides the evolution of the system 
EHLQJPRGHOHGW\SLFDOO\WKHSDWLHQW¶VKHDOWKLQPHGLFDODSSOLFDWLRQVand may enable or 
IRUHFORVHIXUWKHUGHFLVLRQV7KHSDWLHQW¶VKHDOWKat each time point is typically the state, and the 
decisions or actions are identified.  MDPs can be considered as a hybrid between a Markov 
model and a decision tree.   
 
-XVWDVLQ0DUNRYPRGHOVLQDQ0'3DSDWLHQW¶VKHDOWKVWDWHFKDQJHVRYHUWLPHWUDQVLWLRQLQJ
from one discrete state to another according to a specified matrix of probabilities.  However, 
typically in a Markov model, the decision maker has a choice between two or more treatment 
regimens to start the patient on initially.  By contrast, in an MDP, the decision maker can make a 
choice about treatment in every time period.  Thus, it is possible to model at a more granular 
level.  At each time point, one may decide to start, stop or switch treatments, for as long as the 
patient survives.  The constraints may involve the changes in states and/or the decisions.  The 
transition from one state to another is characterized probabilistically. 
 
In this study, the critical decision is when to start statins. Starting statins is taken to be a one-time 
irreversible decision.  Thus, in each time period from age 40 to death - or age 80 - there is a 
ELQDU\³VWDUW´RU³GHOD\´GHFLVLRQ0XFKRIWKHFomplexity of the model is in the modeling of 
the health states.  There are 324 health states describing various combinations of cholesterol and 
high-density lipoprotein levels (3 each), as well as stroke and CHD states (6 each).   
 
Transition probabilities are parameterized based on a proprietary clinical database.  The 
objective function is a combination of health sector costs²such as the cost of treatment 
transacted between the provider, patient, and payer--and net monetary benefit, appropriately 
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discounted over time.  The risk of adverse events is modeled, for comparison through three third-
party risk models. 
 
Different risk-prediction models have estimated probabilities of T2D complications in patients 
based on sociodemographic and environmental risk factors. These predictive models can specify 
the type of treatment to reduce the risk of comorbidity. The most common validated risk models 
from several large studies are the United Kingdom Prospective Diabetes Study (UKPDS), the 
Framingham Heart Study (U.S.) and Archimedes, based on data trial results from the Heart 
Protection Study of 2002.   
 
In particular, the article Optimizing the start time of statin therapy for patients with diabetes[3] 
aimed to identify the optimal decisions for individual patients based on their attributes including 
age, gender, total cholesterol and high-density lipoprotein (HDL).  The authors also performed 
the analyses using the predictions from each of the three risk models above.  Because the choice 
of the risk model may impact the treatment decision, they noted that the predictions from the 
models could be different. 
 
Performing optimization 
The solution method is based on a backward induction approach starting with the last epoch D?. 
Knowing the optimal future actions, the optimal decision at the current epoch can be established 
using recursive optimality in the following equation. 
Recursive optimality: D?ሺD?H?ሻ ൌ D?H?ವ ൣD?ሺD?H?ǡ D?ሺD?H?ሻ൯ ൅  ? D?ሺD?H?H?H?ȁD?H?ǡ D?ሺD?H?ሻሻD?ሺD?H?H?H?ሻሿ׊H?೟శభ  
Where D?ሺD?H?H?H?ȁD?H?ǡ D?ሺD?H?ሻሻD?D?H?D?ሺD?H?ሻ 
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Decision variable: D?ሺD?H?ሻ ൌ ൜ ?D?D? D?D?D?D?D?D?D?D?D?D?D?D?D?D? D? ?D?D? D?D?D?D?D?D?D?D?D?D?D?D?D?D?  D?D?D?D?D?D? H?ᇲ ൌ  ?ǡ D?D?D?D? ሺD?H?ሻ ൌ  ?ǡ ׊D? ൐ D?Ԣ 
 
Sensitivity Analysis 
Where uncertainty in the model existed based on recommended statin starting therapy, the results 
of the optimization approach were tested for the low, medium and high cost of statins across 
willingness-to-pay threshold ranging from $25,000/QALY to $100,000/QALY in $25,000 
increments. This additional analysis provides insight into the value of the model 
recommendations, and whether the recommendation results from using a low- or high-value 
proposition as a starting point. The model was also calibrated to best-available data from that 
time when statins did not have as much information on long-term effectiveness. Given that post-
market knowledge of statin effectiveness is greater now than in 2009, these results express 
uncertainty where greater knowledge now exists. 
 
 
 
Report Results  
The MDP model also unifies results across the three risk models, where there is noticeable 
variability in recommended treatment between studies. The Framingham model determines never 
to initiate statins for three of the nine metabolic states. The Archimedes risk model does not offer 
statin start points for all metabolic states, and predicts statin starting points based on statistical 
inference rather than by generalizable samples of patients, making the model prone to statistical 
error.  
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In contrast, the UKPDS and Framingham risk models fit smoothed Weibull distributions across a 
well-defined population sample. The UKPDS and the Framingham model, give numerically 
different, but qualitatively similar optimal statin start time results. However, using the 
Archimedes risk model in the optimization did not produce a smooth pattern for initiating statin 
therapy as observed with the UKPDS and Framingham models.  The authors attribute this to 
³VWDWLVWLFDOHUURU´ associated with the Archimedes estimates. 
 
The study demonstrates the value of the MDP framework, providing insight into when to start 
statin treatment.  As one would expect, the model generally shows that statins should be started 
earlier IRUPRUHVHYHUHO\LOOSDWLHQWV([DFWO\KRZHDUO\GHSHQGVRQWKHVHYHULW\RIWKHSDWLHQW¶V
condition, but also on model parameters and which risk model is used.  Interestingly, for less 
severe and elderly patients, from the results of Figure 2 in the article, it seems that it may not be 
worthwhile starting statin therapy at all. Women are in general recommended to start statin 
treatment later than men.  
 
 
Decision Making 
The study is an example of how the MDP modeling approach can provide personalized and 
clinically relevant recommendations (for patients of type x, start statins at age y) and integrate 
and compare different data sources and risk models.  As there are many questions about the right 
time to start, stop and switch treatment in medical care, this seems an underused and highly 
promising framework for economic evaluation.  
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Traditional health services research methods focus on efficacy and/or cost-effectiveness at a 
snapshot in time to inform decisions, MDP provides an in-depth modeling and understanding for 
RSWLPDOGHFLVLRQVDWPXOWLSOHWLPHSRLQWVRYHUWKHSDWLHQW¶VGLVHDVHKLVWRU\'XHWRWKHQDWXUHRI
the modeling, it provides the ability to personalize decisions, as opposed to one-size-fits-all 
policies and guidelines established for medical decisions.  However, similar to other approaches, 
MDPs have assumptions based on data and/or the structure of the model.  Once the results are 
obtained, sensitivity analyses can be performed (e.g., for some range of variation in the transition 
probabilities).  Once satisfied with the solution, translation is in the form of guidelines and/or 
decision tools.  Owing to the modeling and computational nature of the MDPs, they can easily be 
translated into decision support systems to use in practice. 
 
This example showed the use of MDP for optimizing the start time of statin therapy.  MDPs can 
be used for other similar decision-making problems for breast or prostate cancer screening, the 
decision for biopsy, initiating HIV therapy treatment policies, etc.  The underlying theme is 
focusing on decisions over time, with decisions at one point affecting future states and decisions 
operating under constrained resources. The results of the optimization models can help establish 
optimal clinical guidelines [35]. 
 
5.  Conclusion 
In this second report, the task force¶Vprimary objective is to provide an overview of areas where 
optimization methods can be applied and describe three case studies illustrating the application 
of constrained optimization methods to critical clinical and health policy questions. The cases 
illustrate several major variants of these methods and demonstrate their potential in 
complementing classical economic evaluation decision-making framework.  
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In the first case study, linear programming methods were used to identify the optimal mix of 
HPV vaccination and screening to minimize the number of cervical cancer cases subject to a 
budget constraint. Similarly, in the second case study, MDP and dynamic programming were 
used to identify the optimal time to initiate statin therapy in type-2 diabetes patients.  The first 
two case studies describe the translation of the original problem into its mathematical 
formulation, its estimation, interpretation, and use.  In contrast, the third is an educational case 
that allows the reader to work through the formulation of a constrained optimization problem 
using the ISPOR Constrained Optimization Good Practice Checklist. 
The healthcare sector faces major challenges with regards to appropriate diagnosis and treatment, 
allocation of scarce resources, designing policies, etc.  These methods provide an approach for 
finding optimal solutions to complex problems in the face of constraints.  As such, they are 
complementary to and build on the health economic models and simulation methods that are 
widely used to guide clinical and policy decision making. 
Constrained optimization methods can improve the current reimbursement decision-making 
processes, which take the budget constraints partially into account. In the constrained 
optimization framework, budget constraints can be incorporated explicitly, together with other 
types of constraints, like human resource or geographical equity constraints. In addition, when 
there are numerous treatment options available for treating patients with a specific condition, 
constrained optimization might prove to be an efficient method for developing treatment 
protocols or guidelines compared to the classical economic evaluation framework. 
In the current healthcare landscape, health economic modeling is widely used to make 
reimbursement decisions for new technologies, particularly outside the United States.  
Constrained optimization methods can help decision-makers incorporate related considerations 
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beyond the reimbursement decision itself including the best way to integrate the new technology 
with the health-care delivery system, as well as in technology disinvestment decisions. These are 
becoming crucial as personalized medicine and performance-based payment concepts become 
more common. 
It is important to recognize that application of constrained optimization methods in healthcare is 
still an emerging area and that there are some challenges that must be addressed.  Constrained 
optimization methods can be limited by data availability and quality, and validating an 
optimization model can be challenging. Choosing and applying the appropriate method can be 
difficult and require specific expertise.  Interpreting results and knowing which solution 
algorithm is likely to be best requires a level of methodological understanding and 
sophistication.    
However, despite these obstacles, the application of constrained optimization methods to health 
care decision making offers substantial potential benefits which make them a valuable addition 
to the arsenal of analytic methods at the disposal of the researcher.  Approaching a problem in 
the context of mathematical optimization forces modelers to identify and quantify the endpoint 
that they are trying to accomplish. But most importantly, constrained optimization takes into 
account the limits placed on the solution by real-world factors such as budgets, availability of 
treatments, staffing capacity, and patient characteristics.  As a result, the identified optimal 
solution is much more likely to be feasible to implement.  
In a disease management problem, by treating patients optimally, we have the potential to 
improve population health and enhance the value associated with health care expenditure. For 
individual patients, this means providing treatment with the proper therapy faster. For 
physicians, this can help provide optimal health outcomes for their patients, enhance the 
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performance of their medical practice, and offer more efficient health care delivery. The task 
force hopes that these two reports will encourage modelers to explore the use of optimization 
methods and looks forward to seeing more published optimization applications and the 
development of further guidelines and resources as the use of these methods becomes more 
widespread. 
APPENDICES 1 & 2  ± See separate document.  
Appendix 1 ± Educational Case 
Appendix 2 ± Model Formulations for the Educational Case  
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Table 1. ISPOR Constrained Optimization Task Force Good Practice Checklist 
Stage Step Description 
Modeling Problem structuring Specify the objective(s) and constraints, 
identify decision variables and parameters, and 
list and appraise model assumptions 
Mathematical formulation Present the objective function(s) and 
constraints in mathematical notation using 
decision variables and parameters 
Model development Program the model in software to estimate the 
objective function(s) and constraints, using 
decision variables and parameters as inputs 
Model validation Ensure the model is appropriate for evaluating 
different combinations of decision variables 
and parameters 
Optimization Select optimization 
method 
 
Choose an appropriate optimization method 
and algorithm on the basis of characteristics of 
the problem. 
Perform 
optimization/sensitivity 
analysis 
Use the optimization algorithm to search for 
the optimal solution and examine the 
performance of the optimal solution for 
reasonable sets of parameters 
 Report results Report the results of the optimal solution and 
sensitivity analyses 
Decision making 
 
Interpret the optimal solution and use it for 
decision making 
Source: Crown et al. 2017, Table 3, p. 315. 
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Discrete representation of patient anatomy 
 
Figure 1: Patient anatomy is discretized into voxels, and treatment beams are discretized into 
beamlets. 
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APPENDICES 
APPENDIX 1 Educational Case Study: Optimizing the Delivery of Radiation Therapy to 
Cancer Patients (Shepard et al., 1999) 
We now challenge the reader to try their hand at formulating alternative models designed to 
optimize radiation therapy using the steps outlined in Table 1. The discussion and modeling 
approach closely follow the seminal work by Shepard, Ferris [1].  A simplified version of the 
originally published mathematical notation and formulations are provided in the appendix for the 
readers to check their formulations. Model formulation is often the most challenging part of 
applying constrained optimization methods, and successful applications typically result from 
multidisciplinary collaboration, involving domain experts on the subject matter as well as the 
modeler. Therefore, one should not feel disappointed if the model specifications do not exactly 
match those provided in the appendix.   
 
There are two main reasons for the selection of radiation treatment planning as the educational 
case study. First, the problem statement is relatively simple to express, and so it is a helpful 
example to showcase several different constrained optimization models (e.g., linear, nonlinear, 
mixed integer). Second, while the problems presented in this educational case study are typically 
studied by operations researchers and medical physicists, the parameters defining treatment goals 
and constraints heavily rely on the health outcomes research findings comparing the 
effectiveness of various cancer treatment protocols and modalities in different patient 
populations. Therefore, we believe that awareness of these treatment planning models can lead to 
new research directions in health outcomes and observational cohort studies.  One such initiative 
is the Oncospace [2], the main goal of which is to create a learning health system that 
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systematically collects relevant clinical data and predicts potential outcomes for specific patient 
characteristics and treatment plan parameters [3, 4].   
 
Shepard, Ferris [1] presented several constrained optimization models for the intensity-
modulated radiation therapy (IMRT) treatment planning problem.  In this setting, a cancerous 
WXPRUZLWKLQDSDWLHQW¶VERGy is targeted with several beams of radiation passing through the 
tumor from different directions since a single beam of radiation strong enough to control the 
growth of the tumor would do unacceptable damage to healthy tissue in its path.  A typical 
objective function in this setting might be to maximize the portion of the tumor region receiving 
a dose of radiation sufficient to prevent further tumor growth while a constraint might be 
ensuring that healthy tissue does not receive damaging levels of radiation dose.  The decision 
variables might be the angles at which the beams are positioned [5] or the intensity of the 
subcomponents of beams, referred to as beamlets [6]. Although the fundamental problem sounds 
straightforward in principle, accurately solving it presents substantial conceptual and 
computational challenges [7-9]. 
 
Background  
IMRT involves radiation sources (photons or protons) outside the body [10]. Several modeling 
techniques have been proposed to optimize IMRT considering the complicating factors such as 
1) the underlying physics and biology; 2) conflicting treatment goals; 3) uncertainties caused by 
daily setup procedures; 4) organ motion and 5) ensuring that the results and facts garnered in the 
course of treatment are efficiently integrated into the treatment plan.   
In clinical practice, radiation therapy is delivered over a period of time as a series of small 
GRVDJHVFDOOHG³IUDFWLRQV´ Dose delivery in each of these treatment sessions is optimized in 
  
43 
 
order to both increase tumor control probability (TCP) and decrease damage to the healthy tissue 
surrounding the tumor by giving it time to recover [11].   
Developing a treatment protocol is complicated - taking multiple considerations into account.  
Randomized control trials and retrospective studies are effective ways of determining the 
efficacy of various treatment protocols. Furthermore, while treatment protocols are designed for 
specific cancer types and patient populations, each patient has unique characteristics, 
comorbidities, tumor location and size, and proximity of tumor region to organs-at-risk (e.g., 
rectum in the case of prostate cancer) and normal tissue. Therefore, radiation therapy treatment 
plans must be optimized to ensure that the treatment protocol requirements are satisfied for each 
patient. The remainder of this section will focus on IMRT treatment planning.  Similar models 
can be used for other radiation therapy modalities as well.  
The steps in the optimization checklist will be followed below. In each step, we will provide 
necessary background information first and then ask the reader questions related to important 
aspects of that step. We will provide sample answers to some questions to assist the reader with 
the modeling exercise.  
 
Problem structuring  
Decisions in radiation treatment planning involve determining the intensity of modulated beams 
and the amount of dose delivered to various points in and around the tumor region. The treatment 
protocol, prescribed by a radiation oncologist, specifies treatment objectives and constraints. For 
example, according to a prostate cancer randomized control trial (RCT) conducted by Pollack et 
al. (2002), delivering 78 Grays of radiation dose to a prostate tumor results in substantial 
improvement in tumor control.  However, the higher doses also increase complications in the 
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rectum, which is an organ-at-risk that needs to be protected from high doses. Using these 
findings as part of a treatment protocol, consider how you would design the objective function to 
ensure that most of the tumor region receives 78 Grays of radiation dose.   
Think about these two possibilities: 
1. For every point in the tumor region, you can calculate the difference between the actual 
dose and the prescribed target dose, i.e., 78 Grays. You can describe an objective 
function that minimizes the largest difference as follows: Minimize the maximum 
difference between the actual and prescribed target doses across all points in the tumor 
region. 
2. Suppose that the radiation oncologist is OK with a small difference (e.g., 2 or 3 grays) 
but wants to avoid large differences (e.g., 10 Grays) from the target dose in the tumor 
region. Similar to the definition above, describe an objective function in such a way that 
the more the dose difference at a certain point in the tumor region from the target dose; 
the more penalty is accrued. Hint: a square of the dose differences can create the desired 
effect. 
Further, how would you impose constraints on dose delivered to the rectum region to avoid 
complications? Again, consider two possibilities: 
1. The radiation oncologist wants to provide overall protection by keeping the dose 
anywhere in the rectum region below 30 Grays. You can define a constraint to this effect 
as follows: The dose at any point in the rectum must be less than 30 Grays. 
2. According to the results from the randomized control trial by Pollack et al. (2002), dose 
escalation results in better outcomes for prostate cancer patients if the portion of the 
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rectal volume receiving 70 Grays or more dose can be kept below 25%. How do you 
define a constraint that ensures this?  
 
Mathematical formulation 
For IMRT optimization, voxels, which are volume elements on a rectilinear grid in a three-
dimensional space (this is analogous to a pixel in three-dimensional space), are identified in the 
anatomy of a patient undergoing radiotherapy as shown in Figure 1. The radiation fields are 
modulated using a multi-leaf collimator (MLC) [12]. Therefore, the radiation beams are regarded 
as bHLQJFRPSULVHGRIPDQ\³EHDPOHWV´VHH)LJXUH. Once voxels and beamlets are determined, 
a dosimetrist calculates how much dose a beamlet of unit intensity can deliver to a voxel.  
Parameters:  
Given these descriptions, think about what parameters are needed to formulate an optimization 
model for IMRT. For example, it may be convenient to introduce notation D?H?, D?H?, and D?H? to 
denote the set of the tumor, organs-at-risk (OAR), and healthy tissue voxels, respectively. One 
parameter is the prescribed target doses of the tumor voxels: D?H? is the target dose for tumor voxel D? א D?H?. 
Now, try to define notation for the following parameters: 
x An upper limit on dose delivered to an organ-at-risk voxel. 
x The dose delivered to a specific voxel by a specific beamlet with unit intensity. 
What other parameters are needed? Compare your parameter definitions with those provided in 
the appendix. 
Decision Variables: 
  
46 
 
There are two sets of decision variables: 1) the intensity of each beamlet; 2) the dose delivered to 
each voxel.  
Introduce notation to define these variables. Compare your variable definitions to those in the 
appendix. 
Objective function and constraints: 
How can you combine these parameters and decisions variables to define an objective function 
and constraints? (Refer to your definitions from the problem structuring step.)  
The specific choice of objective functions and constraints described above will ultimately 
determine the type of constrained optimization model. For example, think about whether a 
simple linear function can be used to model the first objective of minimizing the largest 
difference from a target dose. What type of mathematical function (see the hint provided above) 
can be used to model an objective function that penalizes larger differences from the target dose 
more? Linear or non-linear? 
After attempting to formulate the IMRT optimization problem, compare your formulation with 
the ones in the appendix. 
Advanced considerations: 
If a radiation oncologist is only concerned with limiting the amount of dose delivered to a certain 
region, you can simply use a continuous decision variable representing dose delivered to that 
region and constrain it to be below the desired threshold. If, however, the radiation oncologist is 
interested in sparing only a portion of an organ (i.e., the second constraint possibility described 
in the problem structuring step), then think about what additional (possibly binary) variables you 
need to model this constraint. 
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Compare your new variable and constraint definitions to the alternative formulations provided in 
the appendix. 
Model development  
In this step, the treatment planner implements the model formulation using treatment planning 
software and specialized optimization solvers. The treatment planner makes various decisions 
regarding model parameters and structure. For example, the treatment planner chooses the 
density and location of the voxels to provide a good approximation of the regions of interest 
specified in the treatment protocol. The number and positions of the beams that will deliver 
UDGLDWLRQWRWKHSDWLHQWDUHDOVRFKRVHQEDVHGRQWKHJHRPHWU\RIWKHSDWLHQW¶VDQDWRP\DQG
treatment strategy specified in the protocol. Depending on the location of the tumor, an 
appropriate radiation physics software needs to be used to calculate the dose delivered to a voxel 
from a unit-intensity beamlet. Once all parameters are specified, the model formulation is 
populated with actual parameter values and translated into computer code to communicate with 
an optimization solver. 
Model validation  
The treatment planner goes through several steps to ensure that the model accurately represents 
WKHSDWLHQW¶VDQDWRP\DQGUDGLDWLRQSK\VLFV5REXVWQHVVRIWKHRSWLPL]DWion parameters 
determined in the model development step must be verified in the presence of various 
uncertainties caused by organ motion, setup uncertainty, and potential structural changes to the 
SDWLHQW¶VDQDWRP\GXULQJWKHWUHDWPHQWFRXUVH)RUH[DPSOH multiple dose deposition matrices 
may need to be calculated for different scenarios involving setup errors.  
Select optimization method  
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Selection of the optimization method depends on the model structure and various computational 
considerations depending on the tumor site. The treatment planner must make a trade-off 
between the treatment plan quality and computational time required to obtain it. For example, the 
mathematical formulation of a complex case requiring protection of certain portions of several 
critical organs in the neighborhood of the tumor region might result in a complex mixed-integer 
programming model. Solving such a model to optimality might take multiple hours, making it 
clinically intractable. In this case, the treatment planner may be forced to either change the 
model structure by making certain simplifying assumptions or keep the original mixed-integer 
programming model but use a heuristic method (instead of an exact solution algorithm such a 
branch-and-bound) to obtain a good (but not necessarily optimal) solution in a reasonable 
amount of time. 
Perform optimization/sensitivity analysis 
Optimization of radiation therapy is an iterative process. After solving the mathematical 
formulation, the treatment planner reports the results to the radiation oncologist, who then 
considers several trade-offs between conflicting goals of controlling tumor vs. sparing healthy 
tissue and critical organs. In each iteration, the treatment planner makes changes to the model 
parameters and sometimes to the structure of the model. For example, if the radiation oncologist 
ZDQWVWR³FRROGRZQ´WKHUHFWXPLQRUGHUWRDYRLGFRPSOications, the treatment planner might 
lower the limit on the dose delivered to the rectum. The changes made to the model structure 
may require switching to a different optimization method (compare different optimization 
models and their underlying requirements described in the appendix). 
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The authors of the case study systematically changed various essential parameters, including 
bounds on dose delivered to different regions, objective weights associated with different 
regions, number of beam angles, and relative size of the protected portion of an organ-at-risk. 
Report results  
Following the optimization process, the treatment planner presents the solutions to the radiation 
oncologists. Typically, multiple solutions, obtained through the iterative optimization process, 
are reviewed. The comparisons between these solutions are made using various dose-volume 
histograms, iso-dose curves, and dose distribution heat maps [13]. The authors of the case study 
also used these visualization methods to compare the quality of various treatment plans obtained 
by different optimization models.  
 
Decision making   
After reviewing multiple solutions and considering various trade-offs between conflicting 
treatment goals specified by the protocol, the radiation oncologist chooses a treatment plan, 
which is then delivered in multiple treatment sessions.  
 
Discussion 
A substantial portion of cancer patients undergoes radiation therapy at some point during the 
course of their disease [14]. Optimization models help to make tradeoffs between conflicting 
criteria specified by the treatment protocol and achieve best outcomes for an individual patient.  
This last case described various steps in the optimization checklist to formulate and solve an 
optimization model for the radiation therapy treatment planning problem. The case also 
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illustrated how a given problem could be formulated as a linear program, non-linear program, or 
mixed integer program.  Further details including the advantages and disadvantages of each 
approach are explained in the appendix to provide a learning opportunity for the reader.  
Appendix 2: Model formulations for Educational Case Study (Appendix 1)  
In this section, we guide the reader through the formulation process for the optimization of 
IMRT. 
Parameters:  
x D?H?, D?H?, and D?H? are the set of tumor, organs-at-risk (OAR), and healthy tissue voxels and D? 
is the set of all voxels. D?H?, D?H?, and D?H? are the number of voxels in corresponding regions 
and D? is the number of all voxels. 
x D? is the set of beamlets and by D?H?the intensity of beamlet D? א D?Ǥ D? is the number of all 
beamlets. 
x D?is the D? ൈ D? dose deposition matrix, generated by simulating how an X-ray particle 
deposits energy as it travels through the body of the patient. D?H?H? is an element of D? 
representing the dose delivered to voxel D? by beamlet D? when its intensity is set to unit 
intensity.  
x D?H? is the target dose for tumor voxel D? א D?H?. 
x D?H? and D?H? are the lower and upper bounds on dose delivered to tumor voxels, respectively. 
x D?H? and D?H? are the upper bounds on dose delivered to OAR and healthy tissue voxels, 
respectively. 
Decision Variables: 
x D?H? is the intensity of beamlet D? א D?. 
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x D?H? is the dose delivered to voxel D? א D?. 
Objective function: 
x D?ሺD?Ǣ D?ሻ is the treatment objective function where D? is the vector of doses delivered to 
each voxel and D? is the vector of ``target'' doses for each voxel, as specified by the 
treatment protocol. Several forms of treatment objective functions have been proposed in 
the literature. As described above, one possibility is minimizing the maximum deviation 
from the tumor target dose specified by the treatment protocol: D?ሺD?Ǣ D?ሻ ൌ H? H?אH?೟ ȁD?H?െ D?H?ȁ 
Linear Programming Formulation: 
The IMRT optimization problem can be formulated as a linear program (LP) with the above 
objective function: 
0LQ H?אH?೟ ȁD?H?െ D?H?ȁ (1) 
VXEMHFWWR D?H?ൌ  ෍ D?H?D?H?H?H?אH? ǡ׊D? א D? (2) 
 D?H?൑ D?H?൑ D?H?ǡ׊D? א D?H? (3) 
 D?H?൑ D?H?ǡ׊D? א D?H? (4) 
 D?H?൑ D?H?ǡ׊D? א D?H? (5) 
 ෍ D?H?H?אH?೚ ൑ D?H?D? (6) 
 D?H?൑ D?D?෍ D?H?H?אH? ǡ׊D? א D? (7) 
 D?H?൒  ?ǡ׊D? א D? (8) 
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Even though the objective function (1) is nonlinear, it can easily be converted to equivalent 
linear function by simple variable transformations. Constraint set (2) defines the relationship 
between dose delivered to each voxel and beamlet intensities. Constraint sets (3)-(5) restrict 
maximum and minimum dose received at various treatment regions. Constraint (6) limits mean 
dose delivered to OAR to be lower than a predetermined constant D?Ǥ Constraint set (7) ensures 
that the ratio between maximum and average beamlet intensity does not exceed a predetermined 
constant D? in order to avoid extremely high dose regions in patient anatomy. Finally, constraint 
set (8) ensures beamlet intensities in the optimal solution are positive. 
Nonlinear Programming Formulation: 
Instead of penalizing the maximum deviation from the target dose, the radiation oncologist may 
want to avoid any significant deviations from the target dose. In this case, we can construct an 
objective function with a quadratic penalty for deviating from the target dose.   
 D?ሺD?Ǣ D?ሻ ൌ H? D?H?෍ሺD?H?െ D?H?ሻH?H?אH?೟ ൅ D?H?෍ሺD?H?െ D?H?ሻH?H?אH?೚ ൅ D?H?෍ ሺD?H?െ D?H?ሻH?H?אH?೓ ǡ (9) 
where D?H?, D?H?, and D?H? are weights associated with corresponding regions representing their relative 
importance. The target dose for OAR and healthy tissue is typically zero, meaning that any dose 
delivered is penalized. These weights are determined through an iterative process between the 
treatment planner and radiation oncologist in quest for finding the right trade-off between 
multiple conflicting treatment criteria specified by the treatment protocol. A nonlinear 
programming model can be obtained by replacing objective function (1) with (9).  
Mixed-integer Programming Formulation: 
As mentioned above, according to the results from the randomized control trial by [15], dose 
escalation results in better outcomes for prostate cancer patients if the portion of the rectal 
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volume receiving 70 Grays or more dose can be kept below 25%. These types of requirements in 
treatment protocols are referred to as dose-volume constraints representing the willingness of 
radiation oncologist to sacrifice a portion of an organ-at-risk to improve tumor control. Dose-
volume constraints can be introduced by defining binary variables that indicate whether the dose 
to each voxel in the region of interest is above a certain value (e.g., D?). For example, we can 
define the binary variable for a dose-volume constraint on an OAR, which constrains number of 
voxels in the OAR receiving a dose higher than a specified value, as follows:  
 D?H?ൌ ൜ ?ǡLID?H?൒ D? ?ǡRWKHUZLVH ǡ׊D? א D?H? (10) 
The dose-volume constraint can then be formulated as follows 
 D?H?൑ D?H?൅ D?D?H?ǡ׊D? א D?H?ǡ (11) 
 
 ? D?H?H?אH?೚ ൑ D?D?H?ǡ׊D? א D?H?, (12) 
where D? is the specified percentage and D? is an appropriately large number. 
The variables defined in (10) are required to be binary, which substantially increases 
computation time to find the optimal solution compared to the LP formulation in (1)-(8). 
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